Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Celltrion unveils W100b buyback plan to stabilize stock prices
By YonhapPublished : Jan. 10, 2022 - 16:07
South Korean biopharmaceutical giant Celltrion Inc. on Monday announced a 100 billion-won ($83.3 million) share buyback plan to stabilize stock prices and increase its shareholders' value.
Its affiliate, Celltrion Healthcare, which handles overseas business operations, will also repurchase 50 billion won of its shares.
The buyback plans are scheduled to start Jan. 11 and run until April 10, the companies said, adding their boards of directors made the decisions.
Currently, Celltrion owns 1.32 million shares, and Celltrion Healthcare holds 1.73 million shares. (Yonhap)
Its affiliate, Celltrion Healthcare, which handles overseas business operations, will also repurchase 50 billion won of its shares.
The buyback plans are scheduled to start Jan. 11 and run until April 10, the companies said, adding their boards of directors made the decisions.
Currently, Celltrion owns 1.32 million shares, and Celltrion Healthcare holds 1.73 million shares. (Yonhap)
